A detailed history of Hudson Bay Capital Management LP transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Hudson Bay Capital Management LP holds 100,000 shares of TRVI stock, worth $474,000. This represents 0.0% of its overall portfolio holdings.

Number of Shares
100,000
Previous 50,000 100.0%
Holding current value
$474,000
Previous $167,000 155.09%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$2.53 - $4.5 $126,499 - $225,000
50,000 Added 100.0%
100,000 $426,000
Q3 2024

Nov 13, 2024

BUY
$2.58 - $3.51 $129,000 - $175,500
50,000 New
50,000 $167,000

Others Institutions Holding TRVI

About Trevi Therapeutics, Inc.


  • Ticker TRVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,322,500
  • Market Cap $276M
  • Description
  • Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...
More about TRVI
Track This Portfolio

Track Hudson Bay Capital Management LP Portfolio

Follow Hudson Bay Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Hudson Bay Capital Management LP with notifications on news.